#Sweden #Gothenburg #Vitrolife AB #PGT-A #Igenomix USA

Vitrolife Group Responds to PGT-A Class Action Lawsuit

In a recent development, the Vitrolife Group has issued a formal statement regarding a PGT-A class action lawsuit that has been filed against its subsidiaries Vitrolife AB (publ), Vitrolife Inc, and Igenomix USA, Inc. This legal action is taking place in the Southern District of Florida.

Vitrolife has publicly acknowledged the situation, conveying awareness of the lawsuit despite not having received any formal complaint at this time. This legal scenario follows a wave of similar class action lawsuits that emerged during the fourth quarter of 2024, which targeted not only Vitrolife but also other companies involved in providing PGT-A testing services across the United States.

The company has noted that it will closely collaborate with its legal team based in the U.S. to thoroughly evaluate the specifics and potential ramifications of the class action suit. Vitrolife is committed to keeping its stakeholders informed and plans to provide updates as more information becomes available.

Background on PGT-A Testing

Preimplantation Genetic Testing for Aneuploidy (PGT-A) is a crucial procedure in assisted reproductive technology (ART), allowing for the assessment of embryos prior to implantation. While the technology has been beneficial for many couples, it has also faced scrutiny and legal challenges in recent years, raising questions about the services provided by companies in this sector.

Vitrolife Group has built a reputable standing within the ART community and is known for offering innovative solutions that enhance the success rates of treatments. However, as the recent class actions indicate, the industry remains under intense scrutiny about its practices and product offerings, highlighting the growing oversight of genetic testing services.

The Legal Implications

The implications of such lawsuits can vary significantly, encompassing financial settlements, changes in operational practice, and even regulations governing genetic testing. For Vitrolife, navigating through the ramifications posed by this class action will be a priority, as its impact could resonate through its market position and public perception.

As the situation develops, it is essential for stakeholders, including investors, customers, and healthcare providers, to stay informed. Vitrolife has assured the public that it is ready to tackle this challenge head-on, indicating a proactive approach in managing its legal and operational strategy moving forward.

In conclusion, while Vitrolife Group acknowledges the challenge at hand, it remains dedicated to upholding its commitment to quality and innovation in the field of reproductive health. The company aims to maintain transparency with its community, reinforcing its reputation as a leader in the industry. Further updates will be shared as they come through, ensuring all interested parties are well-informed on the resolution of the matter at hand.

Contact Information

For inquiries regarding this press release, please contact:
Amelie Wilson
Investor Relations
Email: amelie.wilson@vitrolife.com

This article is a summary derived from official statements issued by Vitrolife AB (publ) on March 5, 2025.